Latest Mercator Stories

New research from Mercator Advisory Group reviews key developments in mobile retail payments around the world. Boston, MA (PRWEB) May 02, 2013 Mobile retail payments based on Near Field Communication (NFC) technology are probably this year’s most talked about topic in both the payments industry and the mobile telecommunications industry. NFC is rapidly becoming a standard feature in more smartphones, commercial rollouts are in the works across the globe, and breaking news about new...

TRADING SYMBOL: TSX - ML VANCOUVER, June 27, 2011 /PRNewswire/ - As previously disclosed by the Company on June 22, 2011, Mercator Minerals Ltd. ("Mercator" or the "Company") has acquired all of the issued and outstanding shares of Creston Moly Corp. ("Creston") by way of a plan of arrangement with Creston (the "Arrangement").  Under the terms of the Arrangement, certain former Creston shareholders may be eligible to make a joint Canadian tax election with Mercator in order...

TRADING SYMBOL: TSX - ML VANCOUVER, June 22, 2011 /PRNewswire/ - Mercator Minerals Ltd. ("Mercator" or the "Company") is pleased to announce that it has completed the previously announced arrangement with Creston Moly Corp. ("Creston"), pursuant to which Mercator has acquired all of the issued and outstanding shares of Creston, which is now a wholly owned subsidiary of Mercator. Mercator is also pleased to welcome Bruce McLeod (President and Chief Executive Officer of...

VANCOUVER, April 26 /PRNewswire-FirstCall/ - Mercator Minerals Ltd. ("Mercator" or the "Company") (TSX: ML) announces the appointment of Mr. John H. Bowles, FCA, FCIM, to the Board of Directors of the Company and the resignation of Michael D. Lindeman as a director of the Company, effective April 25, 2011. Mr. Bowles was a Partner in the Audit and Assurance Group of PricewaterhouseCoopers LLP (an accounting firm), where his practice focused on the mining industry, from April 1976...

VANCOUVER, April 12 /PRNewswire-FirstCall/ - Mercator Minerals Ltd. (TSX: ML) ("Mercator") and Creston Moly Corp. (TSXV: CMS) ("Creston") are pleased to announce that they have entered into a definitive arrangement agreement pursuant to which Mercator will acquire all the outstanding common shares of Creston by way of a plan of arrangement. Under the plan of arrangement, shareholders of Creston will receive 0.15 of a common share of Mercator and $0.08 in cash, in respect of each...

WASHINGTON, April 5, 2011 /PRNewswire/ -- Mercator XXI, LLC today announces the release of its 2011 Triangle of Opportunity (TOO) market analysis tool. The publication, which highlights the potent and growing economic potential between China, India and the Middle East, as well as Africa, is being made available to the public in an abridged form. (Logo: http://photos.prnewswire.com/prnh/20110405/PH77932LOGO ) "These two analyses provide a keen look at the synergies that exist between these...

VANCOUVER, March 14 /PRNewswire/ - Mercator Minerals Ltd. ("Mercator" or the "Company") (TSX: ML) is pleased to announce that on March 11, 2011 Standard & Poor's Canadian Index Operations announced the addition of Mercator to the S&P/TSX Composite Index as a result of its quarterly review. The addition will be effective at market open on Monday, March 21, 2011. "The addition of Mercator to the S&P/TSX Composite Index is a result of the substantial increase in market...

SAN LEANDRO, Calif., Feb. 14, 2011 /PRNewswire/ -- Mercator MedSystems, Inc., a privately held medical technology company focused on treating drug-resistant hypertension, announced today that Neil P. Desai, Ph.D. was elected to its Board of Directors. Dr. Desai has an extensive background in drug-delivery and global development and holds over 100 patents in the field. Prior to the acquisition of Abraxis Bioscience, Inc. (ABI), by Celgene Corporation in late 2010, he was Senior...

Plan is Not in Response to any Proposals and is Not Intended to Deter Equitable Transactions VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - Mercator Minerals Ltd. ("Mercator" or the "Company") (ML: TSX) reports that, although it is not aware of any pending or threatened take-over initiatives directed at the Company, Mercator's Board of Directors today approved the adoption of a Shareholder Rights Plan ("Rights Plan"). The Rights Plan is effective today, but is subject to the...

WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides'...